Literature DB >> 29981156

Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.

Yuko Horio1, Koutaro Takamatsu2, Daisuke Tamanoi1, Ryo Sato1, Koichi Saruwatari1, Tokunori Ikeda2,3, Shunya Nakane2,4, Makoto Nakajima2, Sho Saeki1, Hidenori Ichiyasu1, Kazuhiko Fujii1, Yusuke Tomita1.   

Abstract

PD-1 blockade therapy activates T cells by blocking the interaction between PD-1 and PD-L1 and promotes IFN-γ and Th1 cytokine production. In turn, IFN-γ and Th1 cytokines produced by activated T cells promote TF synthesis in monocytes/macrophages, which results in hypercoagulability leading to thrombosis.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Immune checkpoint blockade; Immune-related adverse event; Lung cancer; Tissue factor; Trousseau's syndrome

Mesh：

Substances：

Year:  2018        PMID： 29981156     DOI： 10.1002/eji.201847645

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  8 in total

1.  When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?

Authors:  Michael J Young; Robert W Regenhardt; Leonard L Sokol; Thabele M Leslie-Mazwi
Journal:  AMA J Ethics       Date:  2021-10-01

2.  Immune checkpoint inhibitors for cancer and venous thromboembolic events.

Authors:  Jingyi Gong; Zsofia D Drobni; Raza M Alvi; Sean P Murphy; Ryan J Sullivan; Sarah E Hartmann; Hannah K Gilman; Hang Lee; Leyre Zubiri; Vineet K Raghu; Rebecca S Karp-Leaf; Amna Zafar; Daniel A Zlotoff; Matthew J Frigault; Kerry L Reynolds; Tomas G Neilan
Journal:  Eur J Cancer       Date:  2021-10-15       Impact factor: 10.002

3.  A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.

Authors:  Takayuki Jodai; Chieko Yoshida; Ryo Sato; Yosuke Kakiuchi; Nahoko Sato; Shinji Iyama; Tomoko Kimura; Koichi Saruwatari; Sho Saeki; Hidenori Ichiyasu; Kazuhiko Fujii; Yusuke Tomita
Journal:  Immun Inflamm Dis       Date:  2018-11-21

4.  Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.

Authors:  Satoshi Nakao; Takeshi Masuda; Shinjiro Sakamoto; Kakuhiro Yamaguchi; Yasushi Horimasu; Shintaro Miyamoto; Taku Nakashima; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.

Authors:  Yuta Nakano; Naohiko Koide; Yoshinori Koyama; Kazuhito Nitta; Tomonobu Koizumi
Journal:  Thorac Cancer       Date:  2020-12-21       Impact factor: 3.500

6.  Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.

Authors:  Manuel Sánchez Cánovas; David Fernández Garay; Laura Ortega Moran; Jaime Rubio Pérez; Carlos Miguel Guirao Rubio; Miriam Lobo de Mena; Berta Obispo Portero; Jesús Brenes Castro; Yolanda Lage; Diego Cacho Lavin; Ana Belen Rupérez Blanco; Ana Manuela Martín Fernández de Soignie; Jonatan Zacarías Benoit Perejón; Laura Jiménez Colomo; Noel Blaya Boluda; Javier Bosque Moreno; Teresa Quintanar Verduguez; Carmen Rosa Garrido; Roberto Martín Huertas; Carme Font I Puig; Andrés Jesús Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2022-06-06       Impact factor: 3.340

7.  The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.

Authors:  Koichi Saruwatari; Ryo Sato; Shunya Nakane; Shinya Sakata; Koutaro Takamatsu; Takayuki Jodai; Remi Mito; Yuko Horio; Sho Saeki; Yusuke Tomita; Takuro Sakagami
Journal:  Cancers (Basel)       Date:  2019-01-24       Impact factor: 6.639

Review 8.  Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Authors:  Valli De Re; Laura Caggiari; Ombretta Repetto; Lara Mussolin; Maurizio Mascarin
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.